---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-149624"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:51:49.473639+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kyntra Bio receives Nasdaq delisting notice for failing $50M assets/revenue rule

## Summary
- Received Nasdaq letter on April 2, 2026, for non-compliance with Listing Rule 5450(b)(3)(A) regarding $50M total assets and revenue.
- Non-compliance due to FibroGen International revenue reclassified as discontinued operations in 2024-2025.
- Company has 45 days (by May 18, 2026) to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension.
- Company may consider transferring to Nasdaq Capital Market as alternative.

## SEC filing metadata
- accession: 0001193125-26-149624
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312526149624/0001193125-26-149624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312526149624/kynb-20260402.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-149624
- JSON: https://secwatch.observer/filing/0001193125-26-149624.json
- Plain text: https://secwatch.observer/filing/0001193125-26-149624.txt

## Source-grounded claims
- claim_id: e7e155f4fe96a2cd3d376fd799b967f05aef4c1d
  claim: KYNTRA BIO, INC. received a nasdaq deficiency notice notice regarding other (rules 5450(b)(3)(A)).
  evidence_excerpt: April 2, 2026, Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market notifying us that the Company no longer complies with the Nasdaq Global Select Market continued listing requirement of $50 million in total assets and total revenue for the most recently completed fiscal year (or two of the last three most recently completed fiscal years) per Listing Rule 5450(b)(3)(A). This is due to the revenue of FibroGen International being presented as held for sale (in discontinued operations) in 2024 and 2025. The Comp
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000119312526149624/0001193125-26-149624-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.